A study released on Dec. 2 confirms what many previous studies have already found: Patients given the anti-bleeding drug Trasylol have a higher risk of dying than those who receive less expensive clotting drugs.
Canadian and Australian researchers reviewed findings from 49 randomized clinical trials. While Trasylol (aprotinin) was found to be more effective at controlling blood loss than lysine analogues, the higher fatality rate associated with the drug as well as its expense outweighed the benefits.
Dr. David Henry, one of the co-authors of the study which will be published in the Jan. 20 issue of the Canadian Medical Association Journal, concluded:
“Lysine analogues are almost as effective as aprotinin in controlling blood loss, are cheaper, and appear not to increase mortality.”
Since 2006, several studies have linked Trasylol to an increased risk for kidney damage, stroke and death. If Bayer, the maker of Trasylol, had removed the drug from the market when it learned of the health dangers, it is estimated that 22,000 lives could have been saved.
My law firm currently represents several Trasylol victims and their families in lawsuits against Bayer. The lawyers of Carey, Danis & Lowe are experienced in helping people injured by Trasylol. We will seek compensation for past and future medical expenses, past and future wages, pain and suffering, disability and other damages. We also represent family members in wrongful death cases.
We offer a free initial consultation for victims harmed pharmaceutical products. If you cannot make it to our office, we will come to you at the hospital or your home.
